Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.39 |
| ▸ | FLT1 | P17948 | 11/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 2/20 | 0.34 |
| ▸ | PLAU | P00749 | 2/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18939070 | 0.99 | KDR (0.39) | KDRFLT1NOX1PLGPLAU | |
| SCHEMBL18960808 | 0.91 | NR3C1 (0.36) | NOX1PLGPLAUHDAC11HDAC8 | |
| Hydrochloric Acid SCHEMBL18938987 | 0.90 | NR3C1 (0.36) | NOX1PLGPLAUHDAC11HDAC8 | |
| Hydrochloric Acid SCHEMBL18939177 | 0.88 | KDR (0.38) | KDRFLT1 | |
| SCHEMBL18977806 | 0.87 | KDR (0.39) | KDRFLT1PLGPLAU | |
| SCHEMBL18939153 | 0.85 | PLAU (0.44) | KDRFLT1PLGPLAU | |
| SCHEMBL18951997 | 0.82 | KDR (0.39) | KDRFLT1NOX1PLGPLAU | |
| SCHEMBL18952040 | 0.82 | KDR (0.41) | KDRFLT1 | |
| Hydrochloric Acid SCHEMBL18939085 | 0.81 | KDR (0.39) | KDRFLT1NOX1PLGPLAU | |
| SCHEMBL18939406 | 0.81 | KDR (0.45) | KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48097-E1 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2020-07-14 | — | — | US | disclosed |
| US-9751894-B2 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-09-05 | — | — | US | disclosed |
| US-9751894-B2 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-09-05 | — | — | US | disclosed |
| WO-2017096472-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-06-15 | — | — | WO | disclosed |
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2017-06-15 | — | — | US | disclosed |
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | CEP170, AADAC, NAA50 | KDR 3855/4885FLT1 3469/4885NOX1 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.